News and Insights
The latest news and insights from Genoa Healthcare.
- Behavioral Health
- Clinical Insights
- Treatment
8 frequently asked questions on long-acting injectables
Genoa Healthcare recently hosted a webinar where Senior Product Manager Blake Shoemaker, PharmD, answered frequently asked questions about long-acting injectables (LAIs) and how they can support the people you serve....
- Apr 22nd, 2025
- Partnering with Genoa
- People-first Pharmacy Care
In-house, pharmacy management partnership or outsource? Questions to ask before choosing an on-site pharmacy model
Want to compare your options quickly? Download this overview. You’ve probably heard the benefits of adding a pharmacist to your care team. On-site pharmacies help break down barriers to care,...
- Apr 17th, 2025
- 340B
340B made easy: 5 traits to look for in a contract pharmacy partner
The 340B Drug Pricing Program helps participating organizations – or covered entities – use savings on prescription drug costs to offer more comprehensive services and care for more eligible patients....
- Apr 16th, 2025
- Behavioral Health
- Clinical Insights
- Treatment
Quick guide to recently approved behavioral health medications
Keeping up with new and emerging treatment options for your consumers can be difficult. Genoa Healthcare’s Tim Krause, PharmD, compiled a quick guide to share the latest on recently approved...
- Apr 16th, 2025
- Clinical Insights
- Treatment
Long-acting injectables in practice: What providers need to know
Genoa Healthcare recently hosted a webinar where Senior Product Manager Blake Shoemaker, PharmD, discussed long-acting injectables (LAIs) in practice. Watch the recording below for an overview on benefits, challenges and...
- Apr 10th, 2025
- Behavioral Health
- Clinical Insights
- Treatment
Why medication-assisted treatment is essential for improving patient outcomes
1. Methadone and buprenorphine reduce risk of death after opioid overdose. (2018, June 19). NIH. 2. Methadone and buprenorphine reduce risk of death after opioid overdose. (2018, June 19). NIH....
- Mar 28th, 2025
- 340B
Your questions, answered: 340B manufacturer pricing restrictions
Drug manufacturers began implementing restrictions for 340B pricing in 2020, citing alleged misuse by safety-net providers and explosive growth of the 340B Drug Pricing Program. Since then, restrictions for the...
- Feb 25th, 2025
- Behavioral Health
- Clinical Insights
- Treatment
Currently available and emerging therapy options for treatment-resistant depression
Studies show that 50% of people with major depressive disorder don’t respond adequately to initial antidepressant treatment.1 Additionally, an estimated 30% of people with major depressive disorder (MDD) experience treatment-resistant...
- Feb 24th, 2025
- Art Celebration
- Consumer Stories
- People-first Pharmacy Care
Genoa Art Celebration participant heals through art, helps others after losing daughter to substance use disorder
Content warning: This post discusses mental illness and substance use. Please call the Suicide and Crisis Lifeline at 988, the Substance Abuse and Mental Health Services Administration’s National Helpline at...
- Feb 21st, 2025
- Consumer Stories
- Partnering with Genoa
- People-first Pharmacy Care
Genoa pharmacist turned director reunites with consumer
When Jeannie Barrett, PharmD, transitioned from her role as a pharmacist to director of pharmacy operations for Genoa Healthcare, she wondered if she’d get the chance to see her consumers...
- Feb 20th, 2025